Published in Biotech Business Week, March 31st, 2003
Presented at the American Stroke Association's 28th International Stroke Conference in Phoenix, Arizona, the placebo-controlled study supported the tolerability of Argatroban, showing no statistically significant differences between Argatroban and placebo in symptomatic or asymptomatic intracranial hemorrhage (ICH) which is a major concern in stroke patients receiving...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.